Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Hospital Pharmacies
    • Dosing Calculator
    • Quick Reference
    • Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site

Recommended dosing for treatment of bleeding episodes and surgery1

Keep NovoSeven® RT on hand to treat as soon as possible after a bleeding episode starts. Get an overview of doses for bleeds and perioperative management for each indication.

Recommended dosing for treatment of bleeding episodes and surgery1

Keep NovoSeven® RT on hand to treat as soon as possible after a bleeding episode starts. Get an overview of doses for bleeds and perioperative management for each indication.

Doctor holding glasses

Actor portrayal

For detailed dosing information, please see the Prescribing Information.

Congenital Hemophilia A or B with Inhibitors
(for bleeding episodes)

Before hemostasis is achieved

90 mcg/kg every 2 hours
adjustable based on severity of bleeding, until hemostasis is achieved, or until the treatment has been judged to be inadequate

Calculate a dose for your CHwI patient

After hemostasis is achieved

90 mcg/kg every 3-6 hoursa
after hemostasis is achieved to maintain the hemostatic plug

Acquired Hemophilia
(for bleeding episodes)

70-90 mcg/kg every 2-3 hours until hemostasis is achieved

Calculate a dose for your AH patient

Congenital Factor VII Deficiency
(for bleeding episodes)

15-30 mcg/kg every 4-6 hours until hemostasis is achieved

Effective treatment has been achieved with doses as low as 10 micrograms per kg body weight

Adjust dose and frequency of injections to each individual patient

Calculate a dose for your CFVIId patient

Glanzmann’s Thrombasthenia
With refractoriness to platelet transfusions, with or without antibodies to platelets
(for bleeding episodes)

90 mcg/kg every 2-6 hours in severe bleeding episodes requiring systemic hemostatic therapy until hemostasis is achieved

Platelet transfusions are the primary treatment in patients with Glanzmann’s thrombasthenia without refractoriness to platelets or in patients without platelet-specific antibodies

Calculate a dose for your GT patient

CHwI=congenital hemophilia with inhibitors; AH=acquired hemophilia; CFVIId=congenital factor VII deficiency; GT=Glanzmann’s thrombasthenia

aThe approximate duration of post-hemostatic dosing has not been studied.

For detailed dosing information, please see the Prescribing Information.

Congenital Hemophilia A or B with Inhibitors
(for perioperative management)

Minor

Initial:
90 mcg/kg immediately before surgery
repeat every 2 hours for the duration of the surgery

Post surgical:
90 mcg/kg every 2 hours after surgery for 48 hours then every 2-6 hours until healing occurs

Calculate a dose for your CHwI patient

Major

Initial:
90 mcg/kg immediately before surgery
repeat every 2 hours for the duration of the surgery

Post surgical:
90 mcg/kg every 2 hours after surgery for 5 days then every 4 hours or by continuous infusion at 50 mcg/kg/hr until healing occurs

Acquired Hemophilia
(for perioperative management)

Minor or Major

70-90 mcg/kg immediately before surgery and every 2-3 hours for the duration of surgery and until hemostasis is achieveda

Calculate a dose for your AH patient

Congenital Factor VII Deficiency
(for perioperative management)

Minor or Major

15-30 mcg/kg immediately before surgery and every 4-6 hours for the duration of surgery and until hemostasis is achieveda

Calculate a dose for your CFVIId patient

Glanzmann’s Thrombasthenia
With refractoriness to platelet transfusions, with or without antibodies to platelets
(for perioperative management)

Minor or Major

Initial:
90 mcg/kg immediately before surgery and every 2 hours for the duration of the procedurea

Post surgical:
90 mcg/kg every 2 hours to prevent post-operative bleedinga
Higher doses of 100-140 micrograms per kg can be used for surgical patients who have clinical refractoriness with or without platelet-specific antibodies

Calculate a dose for your GT patient

CHwI=congenital hemophilia with inhibitors; AH=acquired hemophilia; CFVIId=congenital factor VII deficiency; GT=Glanzmann’s thrombasthenia
aThe approximate duration of post-hemostatic dosing has not been studied.

NovoSeven® RT mechanism of action

See how NovoSeven® RT works for CHwI patients.

View MOA video
NovoSeven® RT injection

Patients can use MixPro® to reconstitute NovoSeven® RT.

See the steps

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

Reference
1.    NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020.

Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

NovoSeven® and MixPro® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved.  US21NSVN00130 July 2022

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials